CLRB vs CMPS

Cellectar Biosciences, Inc. vs COMPASS Pathways Plc - American — Valuation Comparison 2026

CLRB

Pharmaceutical Preparations
Cellectar Biosciences, Inc.
Quality
3.7
out of 10
Value Trap
27
LOW
Price
$3.14
Last close
Models
7/13
Active
VS

CMPS

Pharmaceutical Preparations
COMPASS Pathways Plc - American
Quality
1.9
out of 10
Value Trap
12
SAFE
Price
$13.06
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CLRB Fair ValueCLRB Upside CMPS Fair ValueCMPS Upside
Bayesian DCF Intrinsic $1.38 -56.1% $2.95 -77.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.17 -93.7% $0.47 -95.5%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $14.06 +24.7%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CLRB vs CMPS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CLRB vs CMPS — Which Stock Is More Undervalued?

CLRB scores higher with a 3.7/10 quality rating vs CMPS's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cellectar Biosciences, Inc. (CLRB) and COMPASS Pathways Plc - American (CMPS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CLRB currently trades at $3.14 with a QOC of 3.7/10, while CMPS trades at $13.06 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).